Mesoblast Limited (MESO) 2026 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello and welcome to the Mesoblast financial results for the full year ended June 30, 2026.

    各位好,歡迎參加 Mesoblast 截至 2026 年 6 月 30 日止年度的全年財務業績說明。

  • An announcement and presentation have been lodged with the ASX and are also available on the Home and Investors pages at [www.mesoblast.com].

    公告與簡報已提交澳洲證券交易所(ASX),亦可於[www.mesoblast.com] 的首頁與投資人頁面查閱。

  • (Operator Instructions) As a reminder, this conference call is being recorded.

    (接線員指示) 提醒各位,本次電話會議將被錄音。

  • Before we begin, let me remind you that during today's conference call, the company will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events.

    在開始之前,提醒各位:在今天的電話會議中,公司將作出前瞻性陳述,代表公司對未來事件的意圖、預期或信念。

  • These forward-looking statements are qualified by important factors set forth in today's announcement and the company's filings with the SEC, which could cause actual results to differ materially from those such forward-looking statements.

    這些前瞻性陳述受今日公告及公司向美國證券交易委員會(SEC)提交文件中所載的重要因素所限制,該等因素可能導致實際結果與此等前瞻性陳述存在重大差異。

  • In addition, any forward-looking statements represent the company's views only as of the date of this webcast and should not be relied upon as representing the company's views of any subsequent date.

    此外,任何前瞻性陳述僅代表公司於本次網路直播當日的觀點,不應被依賴為代表公司於其後任何日期的觀點。

  • The company specifically disclaims any obligations to update such statements.

    公司明確聲明不承擔更新此等陳述的任何義務。

  • With that, I would now like to turn the call over to Dr. Silviu Itescu, Chief Executive of Mesoblast. Please go ahead.

    接下來,我想把電話交給 Mesoblast 執行長 Silviu Itescu 博士。請開始。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Thank you, operator. Good morning, good afternoon, and thank you all for joining us on Mesoblast's financial results and operational update for the period ended June 30, 2026.

    謝謝接線員。各位早安、午安,感謝各位參加 Mesoblast 截至 2026 年 6 月 30 日止期間的財務業績與營運更新說明。

  • With me are our Chief Financial Officer, Jim O'Brien; Chief Commercial Officer, Marcelo Santoro; and our Head of Orthopedic, Musculoskeletal Program, Roger Brown.

    與我一同出席的有:財務長 Jim O'Brien;商務長 Marcelo Santoro;以及骨科與肌肉骨骼計畫負責人 Roger Brown。

  • If we could go to slide number 2, please. Mesoblast is the leader in allogeneic setting of therapies.

    請切換到第 2 張投影片。Mesoblast 是同種異體治療領域的領導者。

  • RYONCIL, our lead product for mesenchymal stromal cells, is the only FDA-approved product of its type, a first-in-class therapy, and has undergone a successful first-year launch, with net revenues of $115 million for fiscal year 2026, first full year, post-launch.

    RYONCIL 是我們以間質基質細胞(mesenchymal stromal cells)為核心的主力產品,是同類型中唯一獲 FDA 核准的產品,屬於同類首創(first-in-class)療法;上市第一年推進順利,2026 會計年度(上市後第一個完整年度)淨營收達 1.15 億美元。

  • This is a highly profitable single product on a standalone basis and the proceeds from revenues generated from this product are being reinvested in our Phase 3 programs and in our manufacturing for potential blockbuster opportunities.

    就單一產品獨立運作而言,這是一項高度獲利的產品;由該產品所產生的營收所得正再投資於我們的第 3 期計畫,以及製造能力建置,以把握潛在的重磅(blockbuster)機會。

  • We’ve built a mature commercial capability with an infrastructure that supports product launch, growth, and, beyond RYONCIL, multiple expansion indications beyond GVHD and other areas.

    我們已建立成熟的商業化能力,具備可支援產品上市、成長的基礎設施;除 RYONCIL 之外,也能支援多項適應症擴展,涵蓋 GVHD 以外及其他領域。

  • We’ve built a specialized sales team focused on hospitals, transplant centers, and specialists. And we’ve built a robust Phase 3 pipeline with multiple blockbuster opportunities, including chronic low-back pain that I’ll be talking quite a bit on today and inflammatory heart failure.

    我們已建立一支專注於醫院、移植中心與專科醫師的專業銷售團隊。同時,我們也建立了強健的第 3 期研發管線,具備多個重磅機會,包括我今天會談到相當多的慢性下背痛,以及發炎性心衰竭。

  • RYONCIL label expansion beyond GVHD is focused on pediatric -- adults and children, rare inflammatory conditions, such as Duchenne.

    RYONCIL 在 GVHD 之外的標籤擴展,聚焦於兒科——以及成人與兒童的罕見發炎性疾病,例如杜興氏肌營養不良症(Duchenne)。

  • Next slide, please. Our market leadership position is underpinned by our so-called moat. We have a global IP portfolio of more than 1,100 patents and patent applications, which provide commercial protection beyond 2044.

    請看下一張投影片。我們的市場領導地位由我們所謂的「護城河」所支撐。我們擁有超過 1,100 件全球專利與專利申請組合,可提供至 2044 年以後的商業保護。

  • Our dominant IP protects our cells, our manufacturing capabilities, and our multiple indications and commercial opportunities.

    我們具主導性的智慧財產權保護我們的細胞、製造能力,以及多項適應症與商業機會。

  • We have a first-mover advantage in that RYONCIL is the first and only mesenchymal stromal cell product approved by the FDA. We’re leveraging FDA guidance on how approved products such as RYONCIL can be expanded to obtain additional label or new indications.

    我們具備先行者優勢,因為 RYONCIL 是第一個且目前唯一獲 FDA 核准的間質基質細胞產品。我們正運用 FDA 的指引,了解像 RYONCIL 這類已核准產品如何擴展以取得額外標籤或新的適應症。

  • We’ve completed multiple large US-based randomized clinical trials, which continue to provide evidence of efficacy of our platform technologies.

    我們已完成多項在美國進行的大型隨機臨床試驗,持續提供我們平台技術具有效益的證據。

  • We are the leader in complex manufacturing with strong IP protection, significant know-how advantages, and demonstrable FDA alignment, scale-up capability, and ability to leverage across our product pipelines.

    我們在複雜製造方面居於領先地位,具備強大的智慧財產權保護、顯著的專業技術(know-how)優勢,以及可證明的 FDA 對齊、放大生產(scale-up)能力,並能在我們的產品管線間加以運用。

  • And, finally, we’re investing further in our next-generation technology to maintain our leadership position and enhance our tissue-homing characteristics and have new products that leverage our existing development to date.

    最後,我們正進一步投資下一代技術,以維持領導地位、強化組織歸巢(tissue-homing)特性,並推出可延伸我們既有研發成果的新產品。

  • Next slide, please. This slide is a snapshot of our worldwide leadership in allogeneic mesenchymal stromal cell using a portfolio that leverages two major platforms, our rexlemestrocel platform in green and our remestemcel platform in blue.

    請看下一張投影片。本頁為我們在同種異體間質基質細胞領域全球領導地位的快照;我們的產品組合運用兩大平台:以綠色表示的 rexlemestrocel 平台,以及以藍色表示的 remestemcel 平台。

  • As you can see here, the remestemcel platform, branded RYONCIL, is obviously now in the market for children with this life-threatening disease called acute graft-versus-host disease, but is also being expanded in adults in markets that are at least 3 times bigger than the pediatric market.

    如各位所見,remestemcel 平台(品牌為 RYONCIL)目前已在市場上用於治療罹患急性移植物抗宿主病(acute graft-versus-host disease)的兒童,這是一種危及生命的疾病;同時也正擴展至成人市場,其規模至少為兒科市場的 3 倍。

  • The total addressable market for the GVHD opportunity in children and adults is in excess of $1 billion.

    GVHD 在兒童與成人的整體可服務市場(TAM)超過 10 億美元。

  • Remestemcel, or RYONCIL, is also being developed for other rare inflammatory conditions where the underlying mechanism of action can be leveraged beyond GVHD. One of these indications is Duchenne.

    Remestemcel(或 RYONCIL)亦正開發用於其他罕見發炎性疾病;其作用機轉可在 GVHD 之外加以延伸運用。其中一項適應症為杜興氏肌營養不良症(Duchenne)。

  • Duchenne is a very large unmet need in children as young as two to three years old. And these unfortunate children continue to develop inflammation of their muscles, the muscle destruction, and end-organ damage involving the heart and lungs.

    杜興氏肌營養不良症在年僅兩到三歲的兒童中存在極大的未被滿足醫療需求。這些不幸的孩子會持續出現肌肉發炎、肌肉破壞,以及涉及心臟與肺部的終末器官損傷。

  • On the basis of pre-clinical data, plus leveraging the approval of RYONCIL and its mechanism of action, the FDA cleared an IND to commence a Phase 3 trial for potential registration of the product in this very large opportunity.

    基於臨床前數據,並結合 RYONCIL 的核准與其作用機轉,FDA 已核准 IND 以啟動第 3 期試驗,期望在此龐大機會中推進產品的潛在註冊。

  • The second-generation platform, rexlemestrocel, is based on using monoclonal antibodies to isolate an even more potent platform technology of stromal cells that are highly purified and demonstrated significant outcomes across multiple major indications.

    第二代平台 rexlemestrocel,是以單株抗體分離出更具效力的基質細胞平台技術;該細胞高度純化,並在多項主要適應症中展現顯著成果。

  • This platform has been focused on local delivery in the heart, in inflammatory heart disease, and in the orthopedic applications, particularly intervertebral disc disease, where a single injection into the disc space has resulted in substantial and durable long-term reduction in pain.

    此平台聚焦於局部投送:在心臟方面用於發炎性心臟疾病;在骨科應用方面,特別是椎間盤疾病,單次注射至椎間盤腔即帶來顯著且持久的長期疼痛降低。

  • The total addressable markets for rexlemestrocel, just in cardiac disease and in back pain, in aggregate, exceed $20 million -- huge blockbuster opportunities.

    rexlemestrocel 在心臟疾病與背痛領域的可服務市場總計合計超過 2,000 萬美元——是巨大的重磅機會。

  • Next slide, please. Fiscal year 2026 proved to be a successful transition from the R&D company that Mesoblast was to a commercial company with delivery of major milestones.

    請看下一張投影片。2026 會計年度證明 Mesoblast 已成功從以研發為主的公司,轉型為具商業化能力的公司,並達成多項重要里程碑。

  • In our first full commercial year, we were successful in demonstrating a US launch of RYONCIL, with fourth-quarter net revenue of $36 million and annual revenue in first year -- in FY 2026 -- of $115 million. Our gross profit on total sales, excluding amortization expenses, was $110 million.

    在我們第一個完整商業年度中,我們成功證明 RYONCIL 在美國的上市推進:第四季淨營收 3,600 萬美元,且第一年——即 2026 會計年度——年營收達 1.15 億美元。我們的總銷售毛利(不含攤銷費用)為 1.10 億美元。

  • The major milestones that were achieved during the fiscal year were registration trial for label extension of RYONCIL into adults, with steroid-refractory acute graft-versus-host disease that has commenced, and is currently enrolling across more than 40 sites in the Unites States.

    本會計年度達成的主要里程碑包括:RYONCIL 擴展至成人適應症的註冊性試驗已啟動,針對類固醇難治性急性移植物抗宿主病,目前已在美國超過 40 個試驗中心展開收案。

  • A successful IND submission with clearance by the FDA of our Phase 3 trial for pediatric Duchenne; a completion of 350 patients treated in the pivotal randomized controlled Phase 3 trial for the blockbuster indication of chronic low -back pain, this trial seeks to replicate an earlier trial which achieved more than 12 months reduction in pain from a single injection.

    成功提交 IND,並獲 FDA 核准我們針對小兒杜興氏肌營養不良症的第 3 期試驗;以及在重磅適應症——慢性下背痛——的關鍵性隨機對照第 3 期試驗中完成 350 名患者治療;該試驗旨在複製先前一項試驗的結果,該試驗顯示單次注射即可使疼痛減輕超過 12 個月。

  • The total patient numbers, importantly, in this trial increased from 300 patients to 350 patients as a result of strong demand from the trial investigators to have their patients enrolled in this innovative program for patients who, otherwise, have no alternatives.

    值得注意的是,由於試驗研究者強烈要求讓其患者納入這項創新計畫(對於這些患者而言,否則將別無選擇),本試驗的總患者人數由 300 人增加至 350 人。

  • Now, let’s move to our financial update, which will be presented by our Chief Financial Officer, Jim O’Brien.

    現在,讓我們進入財務更新部分,將由我們的財務長 Jim O’Brien 進行報告。

  • James O’Brien - Chief Financial Officer

    James O’Brien - Chief Financial Officer

  • Thank you, Silviu. And good day everybody.

    謝謝你,Silviu。各位大家好。

  • On slide 8, our income statement for the year ended June 2026, as compared to June of 2025.

    請看第 8 張投影片,這是截至 2026 年 6 月止年度的損益表,並與 2025 年 6 月止年度進行比較。

  • Important to note here, as Silvio pointed out, we had $115 million of net revenue for the year, a very exciting year for us that we expect to build on in the future.

    在此要特別指出,如 Silvio 所提到,我們本年度淨營收為 1.15 億美元;對我們而言這是非常令人振奮的一年,我們也預期未來將在此基礎上持續成長。

  • We continued to invest in our R&D programs. Product-development cost for the year were $17.3 million. And our continuing R&D investment in our Phase 3 programs were roughly $21.2 million.

    我們持續投資於研發計畫。本年度產品開發成本為 1,730 萬美元。而我們對第 3 期計畫的持續研發投資約為 2,120 萬美元。

  • We did support the revenue growth of RYONCIL with the increased investment and sales and marketing expenses of roughly about $18 million, with a very strong commercial team now built around the launch. And we continue to penetrate the market and grow market share.

    我們也透過增加投資來支持 RYONCIL 的營收成長,銷售與行銷費用約為 1,800 萬美元;目前已建立一支非常強大的商業團隊以支援上市推廣。我們並持續滲透市場、提升市占率。

  • Importantly, we reduced our net loss after taxes this year by 44% to $57.5 million.

    重要的是,我們今年稅後淨損減少 44%,降至 5,750 萬美元。

  • Next slide, please. Our balance sheet remains very strong. We ended the fiscal year in June with $103 million.

    請看下一張投影片。我們的資產負債表仍然非常強健。我們在 6 月結束的會計年度末持有 1.03 億美元。

  • For the year, net cash usage was $43.8 million, and importantly, in the second half of the fiscal year, our cash burn was $13.4 million compared to $50 million in the same period a year ago.

    本年度淨現金使用額為 4,380 萬美元;更重要的是,在會計年度下半年,我們的現金消耗為 1,340 萬美元,相較於去年同期的 5,000 萬美元大幅下降。

  • We are working towards profitability. We have a very strong cash-flow forecast. Plus, we’re controlling costs in all areas across the businesses. And we’re deploying funds where our operations are most needed to support operations and to continue to grow the company.

    我們正朝向獲利邁進。我們有非常強勁的現金流預測。此外,我們也在業務各領域控管成本。並將資金配置到最需要的營運環節,以支援營運並持續推動公司成長。

  • Our operating plan includes spending money on our Phase 3 programs, building out our manufacturing capabilities, supporting BLA filings, and having the appropriate inventory levels to support patient demand.

    我們的營運計畫包括:投入資金於第 3 期計畫、擴建製造能力、支援 BLA 申請,以及維持適當的庫存水位以滿足患者需求。

  • Earlier this year, as we’ve reported, we entered into a credit-line facility of $125 million, replacing a long-term debt. That carries an 8% interest rate. There is no amortization of the principal for five years.

    今年稍早,如我們所報告,我們簽訂了一項 1.25 億美元的信用額度融資,以取代一筆長期負債。其利率為 8%。本金在五年內無需攤還。

  • Our balance sheet is very strong to support our upcoming fiscal year in terms of being able to deploy capital where we need to.

    我們的資產負債表非常強健,足以支援即將到來的會計年度,讓我們能在需要之處配置資本。

  • Next slide, please. With that, I would like to turn it over to Silviu, again, to take you through our acute [graft-associate-vers-host] disease programs and to address the accomplishments that we have reached, so far, this year.

    請看下一張投影片。接下來,我想把時間交回給 Silviu,再次帶各位了解我們在急性 [graft-associate-vers-host] 疾病計畫上的進展,並說明我們今年迄今所達成的成果。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Thanks, Jim.

    謝謝你,Jim。

  • This next slide summarizes the key accomplishments, so far, for RYONCIL’s commercialization in acute GVHD in children.

    下一張投影片總結了迄今為止 RYONCIL 在兒童急性 GVHD 商業化方面的關鍵成果。

  • Importantly, in green, the real-world experience continues to show the difference we are making in these children and their outcomes, with 84% survival early in the disease process with treatment of RYONCIL in children who, otherwise, would have a very high mortality.

    重要的是,如綠色所示,真實世界的使用經驗持續顯示我們為這些孩子及其預後帶來的改變:在疾病早期使用 RYONCIL 治療的兒童,其存活率達 84%;而若沒有此治療,這些兒童原本將面臨非常高的死亡率。

  • As I mentioned earlier, the net revenue exceeded $125 million since launch of last year. We have now got more than 50 centers onboarded.

    如我先前提到,自去年上市以來,淨營收已超過 1.25 億美元。目前已有超過 50 家中心完成導入。

  • And, importantly, insurance coverage shows that more than 98% of US lives across the country are now covered.

    而且重要的是,保險給付覆蓋顯示,美國全國超過 98% 的受保人目前都已納入保障。

  • Medicaid cover federally was in place early, mandatory in every state. And we were very pleased, having received a J-code in October 2025, which continued to contribute to the growth in revenues.

    聯邦層級的 Medicaid 給付在早期即已到位,且在各州皆為強制性。我們也非常高興於 2025 年 10 月取得 J-code,並持續促進營收成長。

  • Finally, our focus in the next 12 months will be to expand the product adoption in the adult market. And I will talk about that in the next couple of slides.

    最後,我們未來 12 個月的重點將是擴大產品在成人市場的採用。我會在接下來幾張投影片中說明。

  • Next slide, please. So this is a snapshot of strategic approach to continued growth, based on identifying and prioritizing those appropriate patients using various tools at our disposal, reinforcing the superior outcomes, particularly the earlier the product is used, the better the outcome, in these very sick children.

    請看下一張投影片。這張圖概述了我們持續成長的策略作法:運用手邊各種工具來辨識並優先排序合適患者,同時強化優異的治療結果;尤其是產品使用得越早,這些重症兒童的治療結果就越好。

  • We will continue to access reimbursement pull-through and empower caregivers to demand that RYONCIL be used in their children as soon as the disease is diagnosed.

    我們將持續推動給付落地(reimbursement pull-through),並賦能照護者在孩子一經確診時就要求盡快使用 RYONCIL。

  • Next slide. The adult form of this disease is a huge opportunity for RYONCIL growth. There are more than 2,000 adults annually in the US with steroid-refractory graft-versus-host disease. And of these, 50% approximately have got Grade 3 or 4 disease, which is associated with high mortality.

    下一張投影片。此疾病的成人型態為 RYONCIL 的成長帶來巨大機會。在美國,每年有超過 2,000 名成人罹患類固醇難治性移植物抗宿主病。其中約 50% 為第 3 或第 4 級疾病,與高死亡率相關。

  • Ruxolitinib is the only drug that is approved in the US as second-line for adults with acute GVHD. However, only about 42% of patients with the severe form of the disease -- Grade 3 or 4 -- actually achieve a response at day 28 to ruxolitinib.

    Ruxolitinib 是美國唯一核准用於成人急性 GVHD 二線治療的藥物。然而,在重症——第 3 或第 4 級——患者中,實際上僅約 42% 能在使用 ruxolitinib 後第 28 天達到反應。

  • And these patients who do not respond have a very, very dismal survival, as low as 20% to 30% by day 100. So there is a very large unmet need in adults who are currently being treated with ruxolitinib for steroid-refractory acute graft-versus-host disease.

    而這些未反應的患者存活率非常、非常不理想,到第 100 天可能低至 20% 至 30%。因此,對於目前以 ruxolitinib 治療類固醇難治性急性移植物抗宿主病的成人患者而言,仍存在非常龐大的未被滿足醫療需求。

  • In these adults, mortality remains very high. Importantly, those are the very adults who have been enrolled under expanded IND under compassionate care by Mesoblast for treatment with RYONCIL.

    在這些成人患者中,死亡率仍然非常高。重要的是,這些正是 Mesoblast 透過擴大 IND、以同情用藥方式納入並接受 RYONCIL 治療的成人患者。

  • And unlike other therapies which result in, as I said, survival of only 20% to 30%, we’re seeing a 76% survival at day 100 in these patients with terrible outcomes.

    而不同於其他療法(如我所述)僅有 20% 至 30% 的存活率,我們在這些預後極差的患者中觀察到第 100 天存活率達 76%。

  • Next slide, please. This is a slide that provides a snapshot of, on the left-hand side, survival in patients who have failed ruxolitinib as second line and who are then being treated with other agents as third line; and on the right-hand side, patients who have failed ruxolitinib and other second-line agents have then been offered RYONCIL under our compassionate-care program.

    請看下一張投影片。這張投影片提供一個概覽:左側為二線治療 ruxolitinib 失敗後,改以其他藥物作為三線治療的患者之存活情況;右側為 ruxolitinib 及其他二線藥物皆失敗後,於我們的同情用藥計畫下提供 RYONCIL 治療的患者。

  • What you can see here is, on the left-hand side, the day-100 survival where the dotted line is is a dismal 20% to 30%, roughly 25% in this particular report; whereas, on the right-hand side, patients who, otherwise, meet the exact same criteria have a 76% survival -- adolescents and adults -- when they’ve been treated for four to eight weeks with a regimen of RYONCIL.

    您在這裡可以看到的是,左側為第100天存活率,虛線所示僅有令人沮喪的20%至30%,在本報告中約為25%;而右側則顯示,其他條件完全相同的患者——青少年與成人——在接受RYONCIL療程治療四至八週後,存活率可達76%。

  • Therefore, we believe that this is a treatment that should be offered to these patients, a potential adult market of more than 600 patients annually with Grade 3 or 4 disease, refractory, to ruxolitinib or any other agents.

    因此,我們相信這是一項應該提供給這些患者的治療選項;其潛在成人市場為每年超過600名患者,屬於第3級或第4級疾病,且對ruxolitinib或任何其他藥物無反應(難治)。

  • Next slide, please. But even more proximal than that is the entire second-line market in adults with acute graft-versus-host disease. As mentioned earlier, there are more than 2,000 adults who annually develop Grade 3 or 4 disease as part of their disease process after bone-marrow transplant.

    請看下一張投影片。但比這更近端的是成人急性移植物抗宿主病(aGVHD)的整個二線治療市場。如先前所提,每年有超過2,000名成人在骨髓移植後的病程中發展為第3級或第4級疾病。

  • This is a market that’s 3 times bigger than the pediatric market. And this is a market that we have currently addressed through a randomized controlled trial of 180 patients, actively enrolling across the US.

    這個市場規模是兒科市場的3倍。而我們目前已透過一項180名患者的隨機對照試驗來切入此市場,並正在全美積極收案中。

  • These patients in this trial are being randomized one-to-one to ruxolitinib alone versus ruxolitinib plus RYONCIL. We are hoping to see a significant benefit in terms of a day-28 response and a further benefit in overall survival.

    本試驗中的患者以1:1隨機分派至僅使用ruxolitinib,或ruxolitinib合併RYONCIL。我們希望能在第28天反應率方面看到顯著效益,並在整體存活率上獲得進一步改善。

  • And if we’re successful in this trial, RYONCIL would become part of the second-line treatment regimen in these high-risk patients with Grade 3 or 4 disease.

    若我們在此試驗中成功,RYONCIL將成為這些第3級或第4級高風險患者二線治療方案的一部分。

  • This trial is expected to take a total of 18 months to complete, but it will have an interim analysis when approximately 57% of patients are enrolled or close to 100 patients.

    預期本試驗完成總共需要18個月,但在約57%的患者完成收案、或接近100名患者時,將進行期中分析。

  • We expect that interim analysis to be performed in the fourth quarter of 2027. If successful, that would allow us to move forward with a BLA filing for a label extension.

    我們預期該期中分析將於2027年第四季進行。若結果成功,將使我們得以推進BLA申請,以擴增適應症標籤。

  • Next slide. Now, let me move on to what we think is our largest and most exciting near-term blockbuster opportunity. That’s our second-generation pipeline, rexlemestrocel, for chronic low-back pain.

    下一張投影片。接下來我想談談我們認為近期最大、也最令人振奮的重磅機會。那就是我們第二代研發管線產品rexlemestrocel,用於慢性下背痛。

  • The unmet need is substantial. Of the 35 million patients across the US who suffer from chronic low-back pain, about 60%, the cause is degenerative-disc disease, which is an inflammatory condition.

    未被滿足的需求非常龐大。在全美3,500萬名慢性下背痛患者中,約60%的病因是退化性椎間盤疾病,這是一種發炎性病症。

  • And of these, about 7 million fit into our criteria of moderate-to-severe disease within the first five years of diagnosis, refractory to all medical therapies, including opioids.

    在這些患者中,約有700萬人符合我們的條件:於確診後前五年內屬中度至重度疾病,且對所有內科治療(包括鴉片類止痛藥)皆無反應(難治)。

  • The addressable market here is at least USD10 billion. The major milestones to commercial launch are a Phase 3 trial that has completed treatment. All 350 patients have completed treatment.

    此處可觸及市場至少為100億美元。邁向商業上市的主要里程碑是一項已完成治療的第3期試驗。全部350名患者均已完成治療。

  • This Phase 3 trial seeks to confirm an earlier Phase 3 trial, which showed pain reduction at 12 months. This is an FDA-approvable endpoint, as supported by various meetings and documents with the FDA.

    此第3期試驗旨在確認先前一項第3期試驗的結果;該試驗顯示在12個月時疼痛可降低。這是FDA可核准的終點,並已獲得我們與FDA多次會議及文件的支持。

  • The trial read-out is going to be in the second half of calendar year '27, followed by a BLA filing with potential approval in calendar year '28.

    試驗讀出預計在曆年2027年下半年公布,之後將提交BLA申請,並有望於曆年2028年獲得核准。

  • Next slide. This is a diagram that shows what the cause of this severe degenerative disease, back pain, is all about.

    下一張投影片。這張圖示說明了造成此嚴重退化性疾病與背痛的原因。

  • On the left-hand side, you see what a healthy intervertebral disc looks like. On the right-hand side, you see what a degenerative intervertebral disc looks like. In the middle of that area in red, right in the middle of the intervertebral disc, is inflammation. That is where your immune cells come in to try to restore disc integrity.

    左側顯示健康的椎間盤外觀。右側顯示退化的椎間盤外觀。中間紅色區域、也就是椎間盤正中央的位置,是發炎所在。免疫細胞會進入該處,試圖恢復椎間盤的完整性。

  • But in the process of trying to repair, they release a cytokine storm. And many of you are familiar with that term from the COVID period but a cytokine storm, it inadvertently destroys healthy parts of the disc.

    但在修復過程中,它們會釋放細胞激素風暴。許多人在COVID期間對這個名詞並不陌生;細胞激素風暴會在無意間破壞椎間盤中健康的部分。

  • You lose disc height. And you have severe pain as your outcome. That is what we seek to address with a single injection of our cells right in the middle of that inflamed disc.

    椎間盤高度會降低。其結果就是劇烈疼痛。這正是我們希望透過將細胞單次注射至發炎椎間盤正中央來解決的問題。

  • Next slide, please. What is the patient treatment journey in this disease? Well, after conservative treatments that include non-steroidal, anti-inflammatory drugs, there is very little.

    請看下一張投影片。在此疾病中,患者的治療歷程是什麼?在包含非類固醇消炎藥在內的保守治療之後,可用的選項其實非常有限。

  • After patients have failed for three months or more to conservative approaches, many physicians still prescribe opioids. And, unfortunately, opioids are very weak agents that reduce pain.

    當患者以保守方式治療失敗達三個月或更久後,許多醫師仍會開立鴉片類止痛藥。然而不幸的是,鴉片類藥物在降低疼痛方面效果相當有限。

  • They lead to a continued requirement for progressively increasing dosing. There is addiction behavior that is associated with it and, unfortunately, accidental overdosing.

    它們會導致需要持續、逐步增加劑量。並伴隨成癮行為,且不幸的是也可能發生意外過量。

  • Beyond opioids, there really is not anything else that can address the severe, unremitting chronic pain. And so many patients then move on to interventional approaches that are really surgically based.

    在鴉片類藥物之外,幾乎沒有其他方法能處理嚴重且持續不緩解的慢性疼痛。因此,許多患者接著會轉向介入性治療,而這些多半本質上屬於手術導向。

  • And that includes epidural injections that are guided by radiography, but also radiofrequency ablation, spinal-cord stimulation, and intrathecal pumps. Beyond that, all we are left with are severe invasive surgeries.

    其中包括在影像導引下進行的硬膜外注射,也包括射頻燒灼、脊髓刺激,以及鞘內幫浦。再往後,所剩下的就只有高度侵入性的重大手術。

  • So there is a large unmet market that we are targeting to treat moderate-to-severe chronic low-back pain that is totally unaddressed at this point in time.

    因此,我們鎖定的是一個龐大且未被滿足的市場:治療目前完全缺乏有效處置的中度至重度慢性下背痛。

  • Next slide, please. In the earlier Phase 3 trial, which this snapshot is taken from, in 202 patients who received a single injection, in blue, of rexlemestrocel, or in red, rexlemestrocel combined with a carrier, what we see is that significant pain reduction was seen as early as 6 months, maximal by 12 months, and durable through at least 36 months, and in comparison to a saline injection in green, which shows very little effect.

    請看下一張投影片。在先前的第3期試驗中(此處截圖即取自該試驗),202名接受單次注射的患者中,藍色為注射rexlemestrocel,紅色為rexlemestrocel合併載體;我們看到顯著的疼痛降低最早在6個月即出現,於12個月達到最大,且至少可持續至36個月;相較之下,綠色的生理食鹽水注射幾乎沒有作用。

  • Just to put this into context, a very mild reduction in pain from a saline injection is about equivalent to what you would expect to see with opioids. So this is a dramatic reduction in pain that is long-lasting from a single injection.

    為了提供一些背景,生理食鹽水注射所帶來的非常輕微疼痛下降,大致相當於您對鴉片類止痛藥所預期的效果。因此,這是一種由單次注射帶來、幅度顯著且持久的疼痛降低。

  • And these are the data that we are aiming to replicate in the 350-patient pivotal trial that has just completed treatment.

    而這些正是我們希望在剛完成治療、納入350名患者的關鍵性試驗中加以重現的數據。

  • Next slide, please. Now, who are the physicians that administer this product? Today, the dominant caregiver that provides treatment to these patients are the pain specialists in multidisciplinary clinics, where a patient either goes directly or where the patient is referred to from his primary-care physician.

    請看下一張投影片。那麼,哪些醫師會施用這項產品?目前,為這些患者提供治療的主要照護者是多專科診所中的疼痛專科醫師;患者可能直接前往就診,或由其基層照護醫師轉介。

  • Next slide. When we have done a formal outreach, a commercial outreach, to various types of physicians, what you see in this middle panel that is circled, amongst the pain specialists, who are the experts in this space, 85% of them, on reviewing the data from the earlier trial I just showed you, are more likely, on that basis of those results, to recommend rexlemestrocel for chronic low-back pain than anything else, if these results were to be replicated in a commercial product.

    下一張投影片。當我們對各類型醫師進行正式外展、商業外展時,你在中間這個被圈起來的面板所看到的是:在疼痛專科醫師(也就是此領域的專家)之中,有 85% 在檢視我剛才向各位展示的先前試驗數據後,基於那些結果,若這些結果能在商業化產品中被複現,他們更可能推薦 rexlemestrocel 用於慢性下背痛,而非其他任何療法。

  • Next slide, please. Let me move on to our other blockbuster indication, which is chronic heart failure, also from a single injection with rexlemestrocel.

    請看下一張投影片。接著我來談我們另一個重磅適應症:慢性心衰竭,同樣是以 rexlemestrocel 單次注射治療。

  • We are targeting the sickest end-stage patients because that is where the biggest unmet need is today, as we move forward in the broader indications.

    我們鎖定病情最嚴重的末期患者,因為在我們推進更廣泛適應症的同時,這正是目前未被滿足醫療需求最大的族群。

  • Despite an artificial heart, a left ventricular-assist device, that is currently implanted in the left ventricle of these patients who, otherwise, would have a 50% death rate in the first 12 months, the right side of the heart continues to be unprotected, continues to have inflammation, and continues to fail.

    儘管這些患者的左心室目前植入了人工心臟——左心室輔助裝置(LVAD)——否則他們在前 12 個月的死亡率會達到 50%,但心臟右側仍然沒有受到保護,仍然存在發炎,並且持續衰竭。

  • Right-heart failure is the number 1 cause of death in these end-stage patients, despite the fact that they are being kept alive with an artificial heart in the left side of the heart.

    在這些末期患者中,右心衰竭是第一大死因,儘管他們靠左心側的人工心臟維持生命。

  • Next slide, please. And in registry data that cover more than 6,000 patients -- this is very recent data from 2021 and continues to, in 2026, be supported by registry data -- the number 1 cause of both death, hospitalizations, is right-heart failure.

    請看下一張投影片。在涵蓋超過 6,000 名患者的登錄資料中——這是 2021 年的最新資料,並且在 2026 年仍持續有登錄資料支持——死亡與住院的第一大原因都是右心衰竭。

  • And you can see as many as 28% get right-heart failure in these large registry studies. And when you get right-heart failure, you have back-up of blood in your liver and your gut, and you have terrible bleeding. And so so they die of multiple complications, including severe bleeding from the gastrointestinal tract.

    你可以看到,在這些大型登錄研究中,多達 28% 的患者會發生右心衰竭。一旦發生右心衰竭,血液會回流淤積在肝臟與腸胃道,並出現嚴重出血。因此他們會死於多重併發症,包括來自腸胃道的嚴重出血。

  • Next slide, please. Now, a randomized controlled trial was performed in conjunction with the investigators across the US who perform these surgical procedures.

    請看下一張投影片。接著,一項隨機對照試驗與全美執行這些外科手術的研究者合作完成。

  • In that study, at both 6 and 12 months, a single injection of rexlemestrocel reduced by fivefold or more the incidence of major life-threatening gastrointestinal bleeding. And this was due to strengthening of the right side of the heart and reduction in right-sided heart failure.

    在該研究中,於 6 個月與 12 個月時,rexlemestrocel 單次注射可將重大、危及生命的腸胃道出血發生率降低 5 倍或以上。其原因在於強化心臟右側功能並降低右心衰竭。

  • Next slide, please. In addition to reducing bleeding, which was the principal efficacy endpoint in that trial, as you can see here in the top panel, we also reduced hospitalizations from right-heart failure by about fourfold at 12 months in all patients and particularly in those patients at highest risk, which were ischemic patients.

    請看下一張投影片。除了降低出血(這是該試驗的主要療效終點)之外,如你在上方圖表所見,我們也在 12 個月時將所有患者、尤其是最高風險患者(缺血性患者)的右心衰竭住院率降低約 4 倍。

  • And, most importantly, as you can see in the panel below, survival was improved from a 30% mortality rate in these high-risk patients to about 9%. And this was significant.

    而且最重要的是,如你在下方圖表所見,這些高風險患者的存活率有所改善:死亡率由 30% 降至約 9%。而且這具有統計顯著性。

  • Next slide. So our strategy is to file for full approval of REVASCOR in this high-risk patient population at risk of right-heart failure and severe life-threatening bleeding.

    下一張投影片。因此,我們的策略是在這一高風險患者族群(有右心衰竭與嚴重、危及生命出血風險)中,為 REVASCOR 申請完整核准。

  • And if we are successful to gain FDA approval, then this approval can be extended into the much larger patient segment with Class 2 and 3 heart failure, where there is approximately at least 1 million patients in the US alone.

    如果我們成功取得 FDA 核准,該核准可延伸至更大的患者族群——第 2 級與第 3 級心衰竭患者——僅在美國就約至少有 100 萬名患者。

  • Next slide. So in summary, the presentation today has told you what we’ve done, what we intend to do, and how we’re going to do it in the next 12 months.

    請看下一張投影片。總結來說,今天的簡報向各位說明了我們已完成的工作、我們打算做什麼,以及未來 12 個月我們將如何執行。

  • RYONCIL is commercial today. And we seek to have multiple label extensions for this product in order to strongly grow our revenue base.

    RYONCIL 目前已商業化上市。我們希望為此產品取得多項適應症標籤延伸,以強力擴大我們的營收基礎。

  • We seek to increase penetration of the pediatric market, maximize early use, and position the product as both a third-line and a second-line treatment for adults with steroid-refractory graft-versus-host disease, markets that are more than 3 times bigger than the current pediatric market.

    我們希望提高兒科市場滲透率、最大化早期使用,並將本產品定位為成人類固醇難治性移植物抗宿主病(GVHD)的第三線與第二線治療;這些市場規模是目前兒科市場的 3 倍以上。

  • Our focus beyond that is on additional inflammatory diseases, both in pediatric patients and in adult patients. And the first that we’re targeting is Duchenne, which is a pediatric disease that’s progressive without any cures today, that begins as early as three to four years of age.

    除此之外,我們的重點是更多發炎性疾病,涵蓋兒科與成人患者。我們首先鎖定的是杜興氏肌營養不良症(Duchenne),這是一種兒科疾病,目前沒有治癒方法且會持續惡化,最早在 3 到 4 歲就開始發病。

  • In addition, we’re pursuing strategic partnering opportunities for inflammatory conditions in both children and adults with various appropriate strategic partners.

    此外,我們也正針對兒童與成人的發炎性疾病,與多家合適的策略夥伴尋求策略合作機會。

  • For our second-generation pipeline platform, rexlemestrocel, we’ve taken the program right to the end and retained full value in the US market for the blockbuster indication of chronic low-back pain.

    就我們第二代管線平台 rexlemestrocel 而言,我們已將該計畫推進至最後階段,並在慢性下背痛這一重磅適應症上,保留美國市場的完整價值。

  • The pivotal Phase III trial of 350 patients has completed treatment. And we are following these patients through 12 months, with the trial to complete mid-2027 calendar year and then, (inaudible) -- a positive read-out positions us for a BLA filing for a blockbuster indication.

    納入 350 名患者的關鍵性第三期試驗已完成治療。我們將追蹤這些患者至 12 個月,試驗預計於 2027 年曆年年中完成,之後(聽不清)——若讀出結果為正面,將使我們具備就此重磅適應症提交 BLA 申請的條件。

  • Our chronic heart-failure program is -- we seek to complete our BLA filing with the FDA, with the expectation that, if approved, that can be expanded into the much larger Class 2, 3 heart-failure indication, which will be an opportunity for a strategic alliance.

    我們的慢性心衰竭計畫是——我們希望完成向 FDA 提交 BLA 申請;並預期若獲核准,可擴展至規模更大的第 2、3 級心衰竭適應症,這將是一個策略聯盟的機會。

  • On that note, I think I’ll stop. And we would be delighted to take questions. Thank you.

    說到這裡,我想我就先停下來。我們很樂意回答問題。謝謝。

  • Operator

    Operator

  • Thank you. (Operator Instructions)

    謝謝。(接線員指示)

  • Edward Tenthoff, Piper Sandler.

    Edward Tenthoff,Piper Sandler。

  • Edward Tenthoff - Analyst

    Edward Tenthoff - Analyst

  • Great. Thank you very much. And it’s really exciting to see all the progress you guys are making.

    很好。非常感謝。看到你們取得的所有進展,真的令人振奮。

  • I had a question. Great growth from RYONCIL in the current label. Would you hazard a guess to what growth we should be expecting over the next fiscal year? How far do you think we are in terms of penetration of the kids with steroid-refractory GVHD?

    我有一個問題。RYONCIL 在目前標籤適應症下成長很亮眼。你們是否願意大致推估一下,下一個會計年度我們應該期待怎樣的成長?就兒童類固醇難治性 GVHD 的滲透率而言,你們認為目前大概到什麼程度?

  • My second question really came down to, with so many different pediatric inflammatory diseases -- and with the backdrop that DMD’s been tough, there is some competition there. Why did DMD come to the top of the list in terms of secondary indications for childhood inflammation?

    我的第二個問題是:面對這麼多不同的兒科發炎性疾病——而且在 DMD 的背景下,這個領域一直很艱難,也存在一些競爭——為什麼在兒童發炎的次要適應症排序上,DMD 會排到最前面?

  • Thanks a ton, guys.

    非常感謝,各位。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Sure. These are all great questions, Ted. Thank you.

    當然。Ted,這些問題都非常好。謝謝。

  • I think with respect to guidance, I think we’ve only just completed our first year. The next 12 months, we’ll assess it in due course.

    我想就財測指引而言,我們才剛完成第一個年度。接下來 12 個月,我們會在適當時點進行評估。

  • I know that Jim is very keen to review progress. And by mid-year, we’ll have a better sense of continued growth. But we certainly expect to see double-digit growth in the coming 12-month period.

    我知道 Jim 非常希望檢視進展。到年中時,我們會對持續成長有更清楚的掌握。但我們確實預期在接下來 12 個月期間會看到雙位數成長。

  • I think (inaudible) -- your question pertained, also, to our potential areas of growth in new inflammatory conditions. Why Duchenne’s is a great question.

    我認為(聽不清)——你的問題也涉及到我們在新的發炎性疾病中,潛在的成長領域。為什麼選擇杜興氏(Duchenne)是個很好的問題。

  • Duchenne’s a complete unmet need. To your point, there are various people looking at how to use cell therapy in Duchenne’s patients. Most of those people are looking at later-stage disease, 10 years and older, at a point in time when the children are already non-ambulatory.

    杜興氏是一個完全未被滿足的醫療需求。如你所說,目前有各方在研究如何在杜興氏患者中使用細胞治療。其中大多數人著眼於疾病較晚期的患者,10歲以上,在那個時間點孩子通常已經無法行走。

  • At that point, we believe the disease is very late. That’s not where we think we can make the maximal difference and benefit. Maximal benefit, we think, should be obtained in children as early as age three or four, well before the age of nine, for example, when there is maximal inflammation by both T cells; macrophages in the muscles -- in skeletal muscles; and early on, even in the cardiac muscle.

    在那個階段,我們認為疾病已經非常晚期。那不是我們認為能帶來最大差異與效益的時點。我們認為最大的效益應該在孩子三、四歲這麼早就介入,遠早於例如九歲之前;因為在那之前,T細胞與巨噬細胞在肌肉——在骨骼肌——中的發炎最為明顯;而且在早期,甚至在心肌中也會出現。

  • The mechanism of action of our cells with graft-versus-host disease lends itself extremely well to targeting the T-cell process that is going on in the skeletal muscle of these young children.

    我們細胞在移植物抗宿主病(GVHD)中的作用機制,非常適合用來針對這些年幼孩子骨骼肌中正在發生的T細胞過程。

  • If we can turn off that disease early, there woud not be any need for products later on. And, today, there are a number of gene-therapy approaches that aim to improve or bring back some of the normal dystrophin protein.

    如果我們能在早期就關掉這個疾病過程,之後就不會需要後續的產品。而且,目前有多種基因治療策略,目標是改善或恢復部分正常的肌營養不良蛋白(dystrophin)。

  • None of those are going to be curative. And all of those will continue to be accompanied by severe T cell-mediated inflammation of the skeletal muscles.

    但這些都不會是治癒性的。而且所有這些療法仍會伴隨由T細胞介導的嚴重骨骼肌發炎。

  • So we think that we have a unique product built on the mechanism of action in GVHD -- and we’ve demonstrated this in pre-clinical studies -- that is both likely to have a major impact early on in the disease and be additive to the gene therapies that are out there.

    因此我們認為,我們有一個建立在GVHD作用機制之上的獨特產品——而且我們已在臨床前研究中證明——它很可能在疾病早期產生重大影響,並且能與現有的基因治療形成加成效果。

  • Edward Tenthoff - Analyst

    Edward Tenthoff - Analyst

  • That's very helpful. Thank you, Silviu.

    這非常有幫助。謝謝你,Silviu。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Olivia Saunders, Cantor.

    Olivia Saunders,Cantor。

  • Olivia Brayer Saunders - Analyst

    Olivia Brayer Saunders - Analyst

  • Hi. Thank you for the question.

    嗨。謝謝你的提問。

  • What can you guys tell us, at this stage, just around how enrollment is going in the adult GVHD study? And for that interim analysis later next year, is that alone enough for a potential sBLA filing? Or is there anything else the FDA has actually asked for as part of that adult submission?

    你們目前能跟我們分享一下成人GVHD研究的收案進度大概如何嗎?另外,明年稍晚的期中分析,單靠那個就足以支持潛在的sBLA申請嗎?還是FDA其實對於成人適應症的申請,還有要求其他任何資料?

  • And then, also, just wanted to ask about powering for that trial design, if you guys have disclosed that; and how you ultimately decided on a treatment effect on top of jakafi, just in terms of effect size.

    另外也想問一下,關於該試驗設計的統計把握度(power),如果你們有揭露的話;以及你們最終是如何決定在Jakafi基礎上加治療的效果大小(effect size)。

  • Really, just trying to get a better sense for your overall confidence level around enrolling the right patients that will produce a high-enough response rate to hit your stats goal.

    主要是想更清楚了解,你們對於招募到合適患者、以產生足夠高的反應率來達成統計目標的整體信心程度。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Yeah. These are great questions. Let me see if I can take those one at a time.

    是的。這些問題都很好。我看看能不能逐一回答。

  • The basis for starting this trial -- and this trial is being recruited across more than 40 sites in the US, and it's performed in collaboration, in partnership, with the Blood and Marrow Transplant Clinical Trials Network, BMT CTN, which is a network of 80% of all the top bone-marrow transplant centers across the US.

    啟動這項試驗的基礎——而且這項試驗在美國超過40個中心進行招募,並且是與血液與骨髓移植臨床試驗網絡(Blood and Marrow Transplant Clinical Trials Network,BMT CTN)合作、夥伴關係方式執行;BMT CTN涵蓋美國約80%頂尖骨髓移植中心的網絡。

  • So it's been validated by this group, which is an NIH-funded organization, which tells you where the unmet need is because they're driving this indication. The unmet need is in patients with Grade 3, 4 disease who are currently being treated by the only approved drug, ruxolitinib.

    因此這項試驗已由這個團體驗證;該團體是NIH資助的組織,這也說明未被滿足的需求在哪裡,因為是他們在推動這個適應症。未被滿足的需求在於第3級、4級疾病的患者;這些患者目前使用唯一核准的藥物——ruxolitinib——治療。

  • In that group of patients, which is about 50% of the adult GVHD market -- in that group of patients -- ruxolitinib does not perform very well, has not demonstrated a survival benefit with overall response rates in the 50% range.

    在這群患者中——約占成人GVHD市場的50%——ruxolitinib的表現並不好,且未證明有存活獲益;整體反應率大約在50%的區間。

  • So there is a big unmet need because these patients -- if 50% of patients fail ruxolitinib, I showed you earlier, these patients have nothing else beyond that, with a 25% survival at day 100, once they've failed ruxolitinib. That's where the big unmet need is.

    因此存在很大的未被滿足需求,因為這些患者——如果有50%的患者對ruxolitinib失敗——我先前已展示過,一旦ruxolitinib失敗,這些患者就沒有其他選擇;在第100天的存活率只有25%。這就是最大的未被滿足需求所在。

  • We're addressing this market in two different ways. I showed you data where RYONCIL, once ruxolitinib fails, can rescue these patients and get a 76% survival outcome. That's great, but it's a sequence that we and the physicians believe should be addressed even earlier.

    我們以兩種不同方式切入這個市場。我已向各位展示過資料:當ruxolitinib失敗後,RYONCIL可以挽救這些患者,並達到76%的存活結果。這很棒,但我們與臨床醫師都認為,這個治療序列應該更早介入。

  • And so the trial design here is a trial in that group of patients, Grade 3, 4 disease, randomized one to one to ruxolitinib only, where we expect a 50% failure rate, versus ruxolitinib plus RYONCIL, where, based on a single-center pilot study, we would expect to see an overall treatment benefit of at least 75% day-28 response.

    因此,這裡的試驗設計是在這群第3級、4級疾病患者中進行的試驗,採1:1隨機分派至僅使用ruxolitinib(我們預期失敗率為50%),或ruxolitinib加上RYONCIL;根據一項單一中心的先導研究,我們預期可看到至少75%的整體治療效益,即第28天反應率。

  • So that's how the trial has been powered, with the powering approximately 85% to 90%.

    因此本試驗的統計把握度(power)是依此設定,約為85%到90%。

  • Your question was then -- actually, I'm sorry. I believe the expectation is that it'll be about from 50% to about 70% overall response rate.

    你接著的問題是——其實抱歉。我認為預期大概是從50%提升到約70%的整體反應率。

  • Our interim analysis on 57% of patients is based on the assumption that we might do better than that, actually, and achieve a responder rate north of 75%. If we're successful and do achieve that, then 100 patients will be sufficient to declare success.

    我們在57%患者時進行的期中分析,是基於我們可能實際表現更好、達到超過75%反應者比例的假設。如果我們成功並確實達到那個水準,那麼100名患者就足以宣告成功。

  • And so both of those, the full powering of 180 patients and the interim analysis to declare early success, have been vetted with the FDA. And both of those, if we overachieved at the early interim or if we achieved the expected outcome at the full study -- both of those -- would support an sBLA filing.

    因此,無論是完整收案180名患者的統計設計,或是透過期中分析宣告提前成功,這兩者都已與FDA討論並獲得審視。而且這兩種情境——不論我們在早期期中分析超標,或是在完整研究中達到預期結果——都可支持提出sBLA申請。

  • Olivia Brayer Saunders - Analyst

    Olivia Brayer Saunders - Analyst

  • Okay. Great. Thank you.

    好的。了解。謝謝。

  • And have you actually -- are you able to disclose the percent or the number of patients that you've enrolled at this point?

    那你們目前是否能揭露,已收案的患者比例或人數?

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Look, we've enrolled. (multiple speakers) --

    你看,我們已經收案了。(多位講者)——

  • Olivia Brayer Saunders - Analyst

    Olivia Brayer Saunders - Analyst

  • Or suffice it to say you're still feeling good about the interim?

    或者可以說,你們對期中分析仍然感覺良好就足夠了?

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Patients have been enrolled, treated. We expect the hockey-stick effect, as we enroll more by the end of this year.

    患者已經收案並接受治療。我們預期在今年底,隨著收案增加,會出現「曲棍球棒效應」(加速成長)。

  • And then, we expect to have a substantial number on a monthly-accrual basis from January onwards, such that we will have achieved 100 patients roughly by the fourth quarter of next year. We're on track to do that.

    然後我們預期從一月起,以每月收案的基礎會有相當可觀的數量,如此我們大約可在明年第四季達到100名患者。我們正按計畫推進。

  • Operator

    Operator

  • Madeleine Williams, Canaccord.

    Madeleine Williams,Canaccord。

  • Madeleine Williams - Analyst

    Madeleine Williams - Analyst

  • James -- thanks for taking my question -- just as it relates to -- just off the back of the expansion into the adult population, you have mentioned that you have treated adults and adolescents. And there has obviously been some good data that has come out as it relates to that.

    James——謝謝你回答我的問題——就我所提到的——在你們剛將適用族群擴展到成人之後,你們提到已經治療了成人與青少年。而且顯然也有一些與此相關的良好數據出爐。

  • What have the conversations been with the FDA about your capacity to treat the later-stage patients at an earlier time point and how feasible that might be?

    你們與 FDA 就於較早時間點治療較晚期患者的能力進行了哪些對話?以及這在可行性上可能如何?

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Yeah. Look, as you can imagine, those discussions are very active. What I would say is that there is a new leadership at the FDA. And we are very pleased with the new leadership, both at the level of the most senior leadership of the FDA, as well as at the CBER level, as well as the cell- and gene-therapy level.

    是的。你可以想像,這些討論非常積極。我想說的是,FDA 有了新的領導團隊。我們對新的領導團隊非常滿意,無論是在 FDA 最高層級的資深領導、CBER 層級,還是在細胞與基因治療層級。

  • There has been evident flexibility shown by the new leadership in other areas of cell and gene therapy. We are in discussions. And we will have meetings this quarter with the agency to discuss some of these new potential areas of label extension.

    新的領導團隊在細胞與基因治療的其他領域已展現出明顯的彈性。我們正在進行討論。而且我們本季將與主管機關會面,討論一些標籤延伸的新潛在領域。

  • Madeleine Williams - Analyst

    Madeleine Williams - Analyst

  • Thanks for that. And just as it relates to the timeline associated with DMD, you touched on it, but do you have any clear plans to initiate the pivotal trial in that space in the next 12 months?

    謝謝你的說明。另外,就 DMD 相關時程而言,你剛剛有提到,但你們是否有任何明確計畫在未來 12 個月內啟動該領域的關鍵性試驗?

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Well, we certainly do, absolutely. We, at the moment, are in discussions with a group of clinicians across the US to put in place what the appropriate sites need to be and in discussions, also, with the stakeholders of the parents and children to ensure that we have the right groups that can recruit most rapidly and most efficiently.

    嗯,我們當然有,絕對有。目前我們正與全美一群臨床醫師討論,規劃合適的試驗中心應該有哪些;同時也與家長與孩子等利害關係人討論,以確保我們有合適的族群,能以最快、最有效率的方式招募。

  • As soon as all that's in place, the study is ready to begin.

    一旦這些都就緒,研究就可以開始。

  • Madeleine Williams - Analyst

    Madeleine Williams - Analyst

  • Great. And just, finally, from me, and I'll jump back in the queue. Just for the next 12 months and growing RYONCIL in the pediatric business, do you foresee that there'll need to be additional spend in that core business to continue growing the revenue?

    很好。最後一個問題,我問完就回到隊列。就未來 12 個月以及在兒科業務中推動 RYONCIL 成長而言,你是否預期核心業務需要額外支出,才能持續帶動營收成長?

  • James O’Brien - Chief Financial Officer

    James O’Brien - Chief Financial Officer

  • Hey, Madeline. It's Jim O'Brien. Let me try to address that.

    嗨,Madeline。我是 Jim O'Brien。我來試著回答這個問題。

  • I think we've got a good, clear line of sight in our spending on our important Phase 3 programs over the next 12 months. The capital allocation that we have and the plan to do so is crystal clear to us.

    我認為,在未來 12 個月我們對重要第三期計畫的支出方面,我們有很清楚、很良好的能見度。我們的資本配置以及執行計畫,對我們而言非常明確。

  • And execution is of utmost importance in terms of achieving our milestones, as we laid out today, as well as controlling costs and reducing our cash burn.

    在達成我們今天所提出的里程碑方面,執行是最重要的;同時也包括控管成本並降低現金消耗。

  • So our plan for the new fiscal year is to be able to fund the programs that we've outlined today in a very judicious way.

    因此,我們新會計年度的計畫,是以非常審慎的方式為今天概述的各項計畫提供資金。

  • Madeleine Williams - Analyst

    Madeleine Williams - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • John Hester, Bell Potter.

    John Hester,Bell Potter。

  • John Hester - Analyst

    John Hester - Analyst

  • Good morning. A question for Jim.

    早安。有個問題想問 Jim。

  • Jim, just looking at balance sheets, you've got cash of $103 million, net debt of about $15 million, and your cash burn in the second-half, you said, reduced to about $13 million.

    Jim,從資產負債表來看,你們現金為 1.03 億美元,淨負債約 1,500 萬美元,而你說下半年現金消耗已降至約 1,300 萬美元。

  • What is your expectation of the need to raise additional capital at this time?

    你目前對於是否需要再籌集額外資本的預期為何?

  • James O’Brien - Chief Financial Officer

    James O’Brien - Chief Financial Officer

  • Well, I think we want to keep all of our options open.

    嗯,我認為我們希望保留所有選項。

  • With that being said, my expectation is that our cash burn in fiscal '27 will be less than it is in fiscal '26, given the growth of the RYONCIL franchise and the market growth that we expect, cash receipts that we expect.

    話雖如此,我預期 2027 會計年度的現金消耗將低於 2026 會計年度,因為 RYONCIL 產品線的成長、我們預期的市場成長,以及我們預期的現金收款。

  • Our budgets are very clear in terms of where we're allocating capital. And so we'll keep our options open. But, at this time, our balance sheet is very supportive of -- recall that our debt is all long-term. It's got a five-year balloon on it.

    我們的預算在資本配置方向上非常清楚。因此我們會保留選項。但就目前而言,我們的資產負債表非常有支撐力——請記得,我們的債務全部都是長期債務。它有五年的到期一次性償付(balloon)安排。

  • So when I look at the cash balance that we have, our strong working capital, the company's balance sheet can support the growth that we've spoken about today.

    所以當我看我們的現金餘額、強勁的營運資金時,公司資產負債表足以支撐我們今天談到的成長。

  • And we will always look to continue to invest in growth opportunities and be supportive of that, from a financial standpoint.

    而且我們也會持續尋求投資成長機會,並在財務面提供支持。

  • John Hester - Analyst

    John Hester - Analyst

  • And, perhaps, just to follow up, at what quarter do you expect to go cash flow-positive from operations?

    另外追問一下,你預期在第幾季營運現金流會轉正?

  • James O’Brien - Chief Financial Officer

    James O’Brien - Chief Financial Officer

  • Yeah. I'd rather steer away from that question at this point. It's early in our fiscal year. And, as you know, when you talk about spending on R&D programs and enrollment, we're doing a number of projects around manufacturing processes.

    是的。我現在比較想避開這個問題。我們的會計年度才剛開始。而且如你所知,談到研發計畫支出與收案,我們也在製造流程方面進行多項專案。

  • We are the leader in this space. Quarter-by-quarter fluctuations can happen. But we have a clear line of sight in terms of what our priorities are. And Silviu and I are guiding the company towards profitability for the next fiscal year and beyond.

    我們是這個領域的領導者。逐季波動是可能發生的。但我們對自身優先事項有很清楚的能見度。Silviu 和我正帶領公司在下一個會計年度及之後邁向獲利。

  • So quarter by quarter, I think it's a little tough to pin me down on that, but I would expect to see in our future filings this year, certainly. a lower cash burn than we experienced in 2026.

    因此逐季來看,我覺得要我在這點上給出明確時間點有點困難;但我預期在我們今年後續的申報文件中,肯定會看到比 2026 年更低的現金消耗。

  • John Hester - Analyst

    John Hester - Analyst

  • Okay. Thanks. That's all.

    好的。謝謝。就這些。

  • Operator

    Operator

  • Thanks. That brings us to the end of today's call.

    謝謝。今天的電話會議到此結束。

  • I'll now hand back to Dr. Itescu for closing remarks.

    接下來我把時間交回給 Itescu 醫師做結語。

  • Silviu Itescu - Chief Executive Officer, Executive Director

    Silviu Itescu - Chief Executive Officer, Executive Director

  • Great. Thank you, everybody, for joining us today and for the very insightful questions. We hope we've given you a very, very clear trajectory of the company.

    很好。謝謝各位今天參與,也謝謝大家提出非常有洞見的問題。我們希望已為各位提供公司非常、非常清晰的發展軌跡。

  • We've had a terrific year the last 12 months. We think the next 12 months are going to be even more exciting on multiple areas, including growth of our revenue stream for RYONCIL and, most excitedly, about our back-pain blockbuster opportunity.

    過去 12 個月我們表現非常出色。我們認為接下來 12 個月在多個面向會更令人振奮,包括 RYONCIL 的營收成長;而最令人期待的是,我們在背痛領域的重磅(blockbuster)機會。

  • So we look forward to speaking with you all in the short term. Thank you, everybody.

    因此我們期待在短期內再與各位交流。謝謝大家。

  • Operator

    Operator

  • That does conclude our conference for today. Thank you for participating. You may now disconnect.

    今天的會議到此結束。感謝各位參與。您現在可以掛線。